Shares of Omeros (OMER), which had been halted ahead of the company announcing FDA approval of YARTEMLE for treatment of TA-TMA, is scheduled to resume trading at 9:50 am ET, with quotation to resume at 9:45 am ET, according to Nasdaq.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER: